Indaptus Therapeutics, Inc.
INDP
$0.4649
-$0.0151-3.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.93% | -30.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.76% | -23.53% | |||
| Operating Income | -32.76% | 23.53% | |||
| Income Before Tax | -34.60% | 23.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -34.60% | 23.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -34.60% | 23.57% | |||
| EBIT | -32.76% | 23.53% | |||
| EBITDA | -32.76% | 23.53% | |||
| EPS Basic | -17.17% | 31.34% | |||
| Normalized Basic EPS | -17.15% | 31.32% | |||
| EPS Diluted | -17.17% | 31.34% | |||
| Normalized Diluted EPS | -17.15% | 31.32% | |||
| Average Basic Shares Outstanding | 14.87% | 11.31% | |||
| Average Diluted Shares Outstanding | 14.87% | 11.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||